Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 7/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MPL | P40238 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7779423 | 0.83 | EPHX2 (0.50) | PDE2AEPHX2GAATSHRGLA | |
| SCHEMBL29974520 | 0.83 | EPHX2 (0.50) | PDE2AEPHX2GAATSHRGLA | |
| SCHEMBL9367414 | 0.83 | GAA (0.40) | PDE2AEPHX2GAATSHRGLA | |
| SCHEMBL15533987 | 0.82 | ALDH1A1 (0.47) | IDO1GAATSHRPOLBMAPT | |
| SCHEMBL714264 | 0.81 | TSHR (0.48) | PDE2AEPHX2GAATSHRGLA | |
| SCHEMBL6310104 | 0.81 | GAA (0.39) | PDE2AEPHX2GAATSHRGLA | |
| SCHEMBL31533760 | 0.81 | GAA (0.39) | PDE2AEPHX2GAATSHRGLA | |
| SCHEMBL4849499 | 0.79 | APP (0.49) | GAATSHRGLAPOLBMAPK1 | |
| SCHEMBL325072 | 0.78 | GAA (0.36) | PDE2AEPHX2GAATSHRGLA | |
| SCHEMBL22607085 | 0.78 | TSHR (0.45) | PDE2AGAATSHRGLAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0315862-B1 | Aromatically fluorinated fluoromethoxy- and fluoromethylthio-amino benzenes and their preparation | BAYER AG (DE) | 1994-04-13 | — | — | EP | claimed |
| EP-0315862-A2 | Aromatically fluorinated fluoromethoxy- and fluoromethylthio-amino benzenes and their preparation | BAYER AG (DE) | 1989-05-17 | — | — | EP | claimed |
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| US-20250136606-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | US | disclosed |
| EP-4139286-B1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AG (DE) | 2025-02-26 | — | — | EP | disclosed |
| EP-4496569-A1 | CXCR6 SULFONAMIDE COMPOUNDS | ChemoCentryx, Inc. (US) | 2025-01-29 | — | — | EP | disclosed |
| CN-114040911-B | As NAV1.8 2, 3-Dihydro-quinazoline Compounds as inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-08 | — | — | US | disclosed |
| EP-4408850-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | Caraway Therapeutics, Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| CN-118317963-A | TRPML modulators, compositions thereof, and methods of use | 卡拉韦治疗公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-8791255-B2 | (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors | SANOFI (FR) | 2014-07-29 | — | — | US | disclosed |
| CN-103946220-A | Inhibitors of baculovirus containing fragment {2- [4- (biphenyl-4-yl) -1H-imidazol-2-yl ] pyrrolidine-1-carbonylmethyl } amine | THERAVANCE INC | 2014-07-23 | — | — | CN | disclosed |
| EP-2448927-B1 | NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT PHOSPHORYLATION INHIBITORS | SANOFI SA (FR) | 2014-03-12 | — | — | EP | disclosed |
| WO-2013174743-A1 | SUBSTITUTED PYRROLOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-28 | — | — | WO | disclosed |
| US-20120270867-A1 | NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| US-8138175-B2 | Heterocyclyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100022518-A1 | NOVEL HETEROCYCLYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-01-28 | — | — | US | disclosed |
| EP-0315862-B1 | Aromatically fluorinated fluoromethoxy- and fluoromethylthio-amino benzenes and their preparation | BAYER AG (DE) | 1994-04-13 | — | — | EP | disclosed |
| EP-0315862-A2 | Aromatically fluorinated fluoromethoxy- and fluoromethylthio-amino benzenes and their preparation | BAYER AG (DE) | 1989-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270867-A1 | NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | AKT1, AKT2, MTOR | IDO1 3952/4885PDE2A 2541/4885EPHX2 3903/4885 |
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | IDO1 2600/4885PDE2A 1714/4885EPHX2 306/4885 |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | IDO1 4740/4885PDE2A 1077/4885EPHX2 682/4885 |
| US-20100022518-A1 | NOVEL HETEROCYCLYL COMPOUNDS | CCR2, CCR3, CCR5 | IDO1 1522/4885PDE2A 1277/4885EPHX2 1848/4885 |
| US-20250136606-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | MCOLN1, TRPM2, PKD2 | IDO1 4505/4885PDE2A 867/4885EPHX2 4090/4885 |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MYC, MYCBP, GSPT1 | IDO1 2365/4885PDE2A 4376/4885EPHX2 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.